Los Angeles, CA – January 24, 2025 - The Terasaki Institute for Biomedical Innovation- in Los Angeles and the Technology Innovation Institute (TII), the dedicated research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), have started a new collaboration to advance drug discovery and disease modeling related to neurological conditions.
(LOS ANGELES) — It is with a heavy heart that the Terasaki Institute announces the passing of our beloved Chairman of the Board, Dr. Keith Terasaki. Dr. Keith passed away peacefully on the morning of Sunday, December 22, 2024, after a courageous battle with a rare form of lymphoma. His loss is deeply felt by all who had the privilege of knowing him.
(LOS ANGELES) — The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to welcome five new members to its Leadership Board. The TIBI Leadership Board comprises notable visionary individuals who utilize their expertise to promote key initiatives and provide valuable guidance on the institute's research and innovation strategies.
(LOS ANGELES) — The Terasaki Institute for Biomedical Innovation (TIBI) concludes an extraordinary year of scientific discovery and technological innovation that promises to transform healthcare across multiple critical domains. Under the leadership of CEO Dr. Ali Khademhosseini, the institute has made significant strides in bioengineering, regenerative medicine, and personalized healthcare technologies.
(LOS ANGELES) — Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular filler that could transform the way diabetic wounds are treated, potentially improving patient outcomes. The groundbreaking study, published in ACS Nano, introduced an innovative approach about using specialized porous dermal fillers that accelerate tissue healing and regeneration.
(LOS ANGELES) — Researchers at the Terasaki Institute for Biomedical Innovation have developed a novel nanoparticle-based therapy for obesity treatment, as reported in a recent study published in ACS Nano. The innovative approach targets inflammatory cells in adipose tissue, modulating the immune system and promoting fat tissue browning. The research addresses the growing global obesity epidemic and the limitations of current treatment options.
(LOS ANGELES) — Dr. Ali Khademhosseini, Ph.D., CEO and Director of the Terasaki Institute for Biomedical Innovation (TIBI), is honored with the 2024 Andreas Acrivos Award for Professional Progress in Chemical Engineering by the American Institute of Chemical Engineers (AIChE). This distinguished honor recognizes outstanding progress in the field of chemical engineering.
(LOS ANGELES) – Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million grant from the National Institutes of Health (NIH) to advance research in organ transplantation and antibody-mediated rejection. This funding will facilitate the development of an innovative multi-organs-on-a-chip platform aimed at transforming our understanding of transplant rejection and immune tolerance.